Trastuzumab as Adjuvant Treatment for Early Stage HER2-positive Breast Cancer — A 10 Year History

Nowotwory - Poland
doi 10.5603/njo.2016.0085
Full Text
Abstract

Available in full text

Date
Authors
Publisher

VM Media SP. zo.o VM Group SK

Related search

Cost-Utility Analysis of Adjuvant Trastuzumab Therapy for HER2-positive Early-Stage Breast Cancer in the Philippines

BMC Health Services Research
Health Policy
2019English

Trastuzumab Plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer

New England Journal of Medicine
Medicine
2005English

Optimal Treatment of Early Stage HER2-positive Breast Cancer

Cancer
Cancer ResearchOncology
2018English

Pcn74 - A Budget-Impact Analysis of Adjuvant Pertuzumab and Trastuzumab in Early Her2-Positive Breast Cancer

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Adjuvant Chemotherapy and Trastuzumab Is Safe and Effective in Older Women With Small, Node-Negative, HER2-Positive Early-Stage Breast Cancer

Clinical Breast Cancer
Cancer ResearchOncology
2016English

A miRNA-based Signature Predicts Development of Disease Recurrence in HER2 Positive Breast Cancer After Adjuvant Trastuzumab-Based Treatment

Scientific Reports
Multidisciplinary
2016English

Adjuvant Treatment of HER2-positive Breast Cancer: Winning Efforts Continue to Improve HER2-positive Patient Outcome Long-Term

Breast Cancer Research
Cancer ResearchOncology
2012English

Novel Approaches to Target HER2-positive Breast Cancer: Trastuzumab Emtansine

Cancer Management and Research
Oncology
2016English

Adjuvant Chemotherapy Decisions in Clinical Practice for Early-Stage Node-Negative, Estrogen Receptor-Positive, HER2-Negative Breast Cancer: Challenges and Considerations

Journal of the National Comprehensive Cancer Network : JNCCN
MedicineOncology
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy